Multiple Sclerosis Re-Examined: Essential and Emerging Clinical Concepts - 17/04/18
![](/templates/common/images/mail.png)
Neurology Series Editor, William J. Mullally, MD
Abstract |
Multiple sclerosis (MS) is a chronic autoimmune disease of the central nervous system characterized by exacerbations of neurological dysfunction due to inflammatory demyelination. Neurologic symptoms typically present in young adulthood and vary based on the site of inflammation, although weakness, sensory impairment, brainstem dysfunction, and vision loss are common. MS occurs more frequently in women and its development is complex—genetics, hormones, geography, vitamin D, and viral exposure all play roles. Early MS is characterized by relapsing-remitting course and inflammation of the white matter, although as patients age, the disease often transitions to a pathologically distinct secondary progressive phase with gradual disability accrual affecting gait, coordination, and bladder function. A minority of patients (10%) have disease that is progressive at onset. In the past decade, there has been a remarkable expansion in disease-modifying therapy for MS, but treatment of progressive disease remains a challenge. This article reviews foundational concepts in MS and emerging work that has reshaped understanding of the disease, providing new insight for therapeutic advance.
Le texte complet de cet article est disponible en PDF.Keywords : Disease-modifying treatment, MS diagnosis, MS pathology, Multiple sclerosis
Plan
Funding: None. |
|
Conflicts of Interest: JS has consulted with Teva Neuroscience, Genzyme, Hoffman-Laroche, Biogen Idec, Novartis, and Bayer. JZ has no conflicts of interest to disclose. |
|
Authorship: Both authors had access to the data and a role in writing this manuscript. |
Vol 131 - N° 5
P. 464-472 - mai 2018 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?